Activation of AXL and antitumor effects of a monoclonal antibody to AXL in lung adenocarcinoma

Anticancer Research

Volumn 34, Issue 4, 2014, Pages 1821-1828

  Iida, Shinya ^a   Miki, Yasuhiro ^a   Suzuki, Takashi ^a   Mori, Kazushige ^b   Saito, Mikiyoshi ^b   Niikawa, Hiromichi ^c   Kondo, Takashi ^d   Yamada Okabe, Hisafumi ^b   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c TOHOKU UNIVERSITY HOSPITAL   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

Author keywords

AXL; Lung adenocarcinoma; Monoclonal antibody therapy

Indexed keywords

ANEXELEKTO; ANTINEOPLASTIC AGENT; GROWTH ARREST SPECIFIC PROTEIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AXL; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR;

A549 CELL LINE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ADENOCARCINOMA; AGED; AXL; DRUG ANTAGONISM; DRUG EFFECT; LUNG TUMOR; METABOLISM; MIDDLE AGED; MONOCLONAL ANTIBODY THERAPY; MORTALITY; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; TUMOR CELL LINE; TUMOR VOLUME;

AXL; LUNG ADENOCARCINOMA; MONOCLONAL ANTIBODY THERAPY;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; TUMOR BURDEN;

EID: 84902261040     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Lai C and Lemke G: An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron 6: 691-704, 1991.
2. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R 3rd, Ke Beau MM, Earp HS and Liu ET: Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11: 5016-5031, 1991.
3. Lemke G and Rothlin CV: Immunobiology of the TAM receptors. Nat Rev Immunol 8: 327-336, 2008.
4. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, Mattsson K, Fosher J, Gies DR, Jones PF, Masiakowski P, Ryan TE, Tobkes NJ, Chen DH, DiStefano PS, Long GL, Basilico C, Goldfarb MP, Lemke G, Glass DJ and Yancopoulos GD: The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 80: 661-70, 1995.
5. Godowski PJ, Mark MR, Chen J, Sadick MD, Raab H and Hammonds RG: Reevaluation of the roles of protein S and Gas6 as ligands for the receptor tyrosine kinase Rse/Tyro 3. Cell 82: 355-358, 1995.
6. Mark MR, Chen J, Hammonds RG, Sadick M and Godowsk PJ: Characterization of Gas6, a membrane of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl. J Biol Chem 271: 9785-9789, 1996.
7. Varnum BC, Yound C, Elliott G, Garcia A, Bartley TD, Fridell YW, Hunt RW, Trail G, Clogston C, Toso RJ, Yanagihara D, Bennett L, Sylber M, Merewether LA, Tseng A, Escobar E, Liu ET and Yamane HK: Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth arrest-specific gene 6. Nature 373: 623-626, 1995.
8. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H and Mizuno K: Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 271: 30022-30027, 1996.
9. Hafizi S and Dahlbäck B: Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J 273: 5231-5244, 2006.
10. Linger RM, Keating AK, Earp HS and Graham DK: TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 100: 35-83, 2008.
11. Ruan GX and Kazlauskas A: AXL is essential for VEGF-A-dependent activation of PI3K/AKT. EMBO J 31: 1692-1703, 2012.
12. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 103: 211-225, 2000.
13. Bellosta P, Costa M, Lin DA and Basilico C: The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Mol Cell Biol 15: 614-625, 1995.
14. Burchert A, Attar EC, McCloskey P, Fridell YW and Liu ET: Determinants for transformation induced by the Axl receptor tyrosine kinase. Oncogene 16: 3177-3187, 1998.
15. Taylor IC, Roy S and Varmus HE: Overexpression of the Sky receptor tyrosine kinase at the cell surface or in the cytoplasm results in ligand-independent activation. Oncogene 11: 2619-2626, 1995.
16. Budagian V, Bulanova E, Orinska Z, Thon L, Mamat U, Bellosta P, Basilico C, Adam D, Paus R and Bulfone-Paus S: A promiscuous liaison between IL-15 receptor and AXL receptor tyrosine kinase in cell death control. EMBO J 24: 4260-4270, 2005.
17. Hector A, Montgomery EA, Karikari C, Canto M, Dunbar KB, Wang JS, Feldmann G, Hong SM, Haffner MC, Meeker AK, Holland SJ, Yu J, Heckrodt TJ, Zhang J, Ding P, Goff D, Singh R, Roa JC, Marimuthu A, Riggins GJ, Eshleman JR, Nelkin BD, Pandey A and Maitra A: The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther 10: 1009-1018, 2010.
18. Wu CW, Li AF, Chi CW, Lai CH, Huang CL. Lo SS, Lui WY and Lin WC: Clinical significance of AXL kinase family in gastric cancer. Anticancer Res 22: 1071-1078, 2002.
19. Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA and Giaccia AJ: AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res 70: 7570-7579, 2010.
20. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS and Wu CW: Expression of Axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 7: 1058-1064, 2005.
21. Ishikawa M, Sonobe M, Nakayama E, Kobayashi M, Kikuchi R, Kitamura J, Imamura N and Date H: Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients. Ann Surg Oncol 2012 (Epub ahead of print).
22. Wimmel A, Glitz D, Kraus A, Roeder J and Schuermann M: Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer 37: 2264-2274, 2001.
23. Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, Weimer R, Wu Y and Pei L: An anti-AXL monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29: 5254-5264, 2010.
24. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD and Heymach JV: An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies AXL as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19: 279-290, 2013.
25. Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ and Chuang SE: Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res 67: 3878-3887, 2007.
26. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B and Bivona TG: Activation of the AXL kinase causes resistance to EGFRtargeted therapy in lung cancer. Nat Genet 44: 852-860, 2012.
27. Rettew AN, Young ED, Lev DC, Kleinerman ES, Abdul-Karim FW, Getty PJ and Greenfield EM: Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Oncogenesis e34, 2012.
28. Garcia-Echeverria C and Sellers WR: Drug discovery approaches targeting the PI3K/AKT pathway in cancer. Oncogene 27: 5511-5526, 2008.
29. Roberts PJ and Der CJ: Targeting the RAF-ERK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007.
30. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, Zhang J, Ding P, Apatira A, Chua J, Brandt R, Pine P, Goff D, Singh R, Payan DG and Hitoshi Y: R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 70: 1544-1554, 2010.
31. Johnson KA and Brown PH: Drug development for cancer chemoprevention: focus on molecular targets. Semin Oncol 37: 345-358, 2010.
32. Shankar SL, O'Guin K, Cammer M, McMorris FA, Stitt TN, Basch RS, Varnum B and Shafit-Zagardo B: The growth arrest-specific gene product GAS6 promotes the survival of human oligodendrocytes via a phosphatidylinositol 3-kinase-dependent pathway. J Neurosci 23: 4208-4218, 2003.
33. Hasanbasic I, Cuerquis J, Varnum B and Blostein MD: Intracellular signaling pathways involved in Gas6-Axl-mediated survival of endothelial cells. Am J Physiol Heart Circ Physiol 287: H1207-H1213, 2004.
34. Melaragno MG, Cavet ME, Yan C, Tai LK, Jin ZG, Haendeler J and Berk BC: Gas6 inhibits apoptosis in vascular smooth muscle: role of Axl kinase and Akt. J Mol Cell Cardiol 37: 881-887, 2004.
35. Valverde P, Obin MS and Taylor A: Role of Gas6/Axl signaling in lens epithelial cell proliferation and survival. Exp Eye Res 78: 27-37, 2004.
36. Stenhoff J, Dahlbäck B and Hafizi S: Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts. Biochem Biophys Res Commun 319: 871-878, 2004.
37. Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P and Avanzi GC: Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol 204: 36-44, 2005.